

1st open meeting of the COST Action CA19114



9-11th of May 2022, Gothenburg, Sweden,

University of Gothenburg site "Medicinareberget"

Agenda

Monday May 9th

Lecture hall Arvid Carlsson & Venue hall Birgit Thilander – Academicum, Medicinaregatan 3		
17.30	Welcome announcement	Emma Aneheim – Vice Chair
17.45	Invited speaker – situation in Japan	Kohshin Washiyama – Fukushima Medical University, Japan
18.30	Q&A from the audience	
18.40	Presentation of COST-NOAR	Jean-Francois Gestin - Action Chair
19.00	Welcome reception and mingle	

Tuesday May 10th

University of Gothenburg Conference Center Wallenberg, Hall Europe		
09.00	Official meeting opening	Jean-Francois Gestin/ Emma Aneheim
09.05	Invited speaker – situation in USA	Scott Wilbur - University of Washington, USA
09.50	Q&A from the audience	
10.00	<i>Coffee Break</i>	<i>Industrial exhibition + poster viewing</i>
10.30	Invited speakers – situation in Europe	Holger Jensen - Copenhagen University Hospital, Denmark / Sture Lindegren - University of Gothenburg, Sweden
11.15	Q&A from the audience	
11.25	A few words from the COST office	Jeannette Nchung Oru - COST
11.55	STSM introduction	Marek Pruszynski
12.00	STSM presentations	Chiara Timperanza, Matthijs Sevenois
12.25	Information for the remainder of the day	Emma Aneheim
12.30	<i>Lunch</i>	
13.30	Parallel Working Group (WG) 1,2,3,4,5-meetings	Hall: Europe, Asia, North America, South America, Antarctica
15.00	<i>Joint Coffee Break</i>	<i>Industrial exhibition + poster viewing</i>
15.30	Parallel Working Group (WG) 1,2,3,4,5-meetings	Hall: Europe, Asia, North America, South America, Antarctica
17.00	End of day 1	

19.00	Official Dinner Event	Skansen Kronan
-------	-----------------------	----------------

Wednesday May 11th

University of Gothenburg Conference Center Wallenberg, Hall Europe		
09.00	Full meeting discussions: Targetry, production, extraction, back-up & logistics (WG 1) Clinical applications (WG 4)	<i>Ca 30 min per topic, discussion leader:</i> Sture Lindegren Jose Reinaldo Chicharo de Freitas
10.00	<i>Coffee Break</i>	<i>Industrial exhibition + poster viewing</i>
10.30	Full meeting discussions: -Improving Dosimetry (WG 3) -Radiopharmaceuticals –Chemistry (WG2-1) -Radiopharmaceuticals –Biology (WG2-2) Discussion on valorisation of project results (WG 5)	<i>Ca 30 min per topic, discussion leader:</i> Stig Palm Francois Guerard Joëlle Gaschet Dana Niculae
12.30	<i>Lunch</i>	
13.30	Panel discussion on the future of astatine	Industrial participants: Novartis, IBA, lonetix, Atley, Atonco, Precirix + Academic representatives
14.30	Q&A from the Audience	
15.00	<i>Coffee Break</i>	<i>Industrial exhibition + poster viewing</i>
15.30	Meeting summary and official closing of the open meeting	Jean-Francois Gestin/ Emma Aneheim

15.45	MC meeting	All representatives of the MC
16.30 - 17.00	Core Group meeting	NOAR Core group

Meeting sponsors:



**JUBILEUMSKLINIKENS
CANCERFOND**

WG1- Astatine-211 targetry, production, extraction, back-up, logistics

Objective: To ensure reliable and sustainable astatine-211 production and development of a standardized purification method.

This WG focus on astatine-211 production in order to ensure reliable access to inject patients with therapeutic doses of qualified astatine-211 within the ATNodes in Europe.

WG2 - Radiopharmaceuticals: development and preclinical Proof of Concept

Objective: Development of radiolabelling strategies adapted to different vectors.

This WG focus on building different astatine-211 radiolabelled vectors in order to establish the preclinical proof of concept for some of them that will be pushed forward through the clinical development.

WG3 - Improving Dosimetry for Optimizing Targeted Alpha Therapy with astatine-211

Objective: Construct and validate computer models for estimating absorbed dose to tumours and healthy tissues.

This WG focus on dosimetry to predict efficacy and risks associated to the use of the different astatine derivatives.

WG4 - Clinical applications in Nuclear Medicine

Objective: Feedback and standardization of clinical practices.

This WG focus on establishing which pathologies are best adapted to benefit from treatment with astatine-211 targeted therapy and prove the clinical potential. It will also focus on the organizational, regulation and economic aspects in order to evaluate the European practices and to propose a standardization of practices.

WG5 - Valorisation of project results: exploitation, dissemination, communication

Objective: Make the technology visible and accessible to researchers, patients, EU practitioners and industrials.

This WG focus on creating the conditions to leverage the barriers to the development of astatine-therapy by identifying therapeutical candidates and creating transfer and development conditions.